Keyword: Zurampic

Zurampic, a drug AstraZeneca once laid out more than $1 billion to get its hands on, has wound up on the scrap heap.

What do constipation and gout have in common? Ironwood is leveraging its primary care sales force to hawk meds to treat both.

Growing the gout market has been slow going for Ironwood. But now, the company has a new catalyst.

AstraZeneca snagged $250 million-plus for its cancer drug Zoladex in the U.S., where it brought in only $69 million last year. The deal, AZ's latest slim-down maneuver, also includes a share of ongoing sales.

Earlier this year, AstraZeneca sold off the U.S. marketing rights to gout drug Zurampic--and now it’s unloading the European and Latin American rights, too.

Did Ironwood Pharmaceuticals just pick up a promising product, or did AstraZeneca just unload a problematic one? You be the judge: Ironwood says it will pay up to $265 million in cash plus royalties for the chance to market AstraZeneca’s recently approved gout drug Zurampic.